Showing results (251-260 of 289) with videos related to
Sort By:
Pageof 29
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.The Journal of Urology|July 22, 2014
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinomaMatteo Santoni, Alessandro Conti, Camillo Porta, et al.Clinical Genitourinary Cancer|August 31, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 StudyGiuseppe Fotia, Calogero Saieva, Richard Lee-Ying, et al.Urologic Oncology|April 25, 2015
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and youngerOrazio Caffo, Cinzia Ortega, Giuseppe Di Lorenzo, et al.Nature Communications|May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialPadmanee Sharma, Michael Krainer, Fred Saad, et al.The Oncologist|December 2, 2025
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort studyLorena Incorvaia, Mattia Puglisi, Marco Maruzzo, et al.JAMA Network Open|November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving NivolumabMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.Journal of Clinical Pathology|November 4, 2020
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinomaMatteo Brunelli, Alessandro Tafuri, Luca Cima, et al.Pageof 29